These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 28098353)

  • 1. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
    Hong F; Xu P; Zhai Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
    Heald M; Cawthorne MA
    Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
    Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ
    Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next generation of PPAR drugs: do we have the tools to find them?
    Shearer BG; Billin AN
    Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
    Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
    Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.
    Khuchua Z; Glukhov AI; Strauss AW; Javadov S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors and atherosclerosis.
    Soskić SS; Dobutović BD; Sudar EM; Obradović MM; Nikolić DM; Zarić BL; Stojanović SD; Stokić EJ; Mikhailidis DP; Isenović ER
    Angiology; 2011 Oct; 62(7):523-34. PubMed ID: 21467121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
    Grygiel-Górniak B
    Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
    Mirza AZ; Althagafi II; Shamshad H
    Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.